Lexagene Holdings Inc LXXGQ

Healthcare Medical Devices

Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.

GREY:LXXGQ - Post by User

Lexagene Holdings Inc > new video on twitter 56 mins ago

<< Previous

Bullboard Posts

Next >>

Comment by Investor62on Apr 15, 2020 9:38am

68 Views

Post# 30911068

RE:RE:RE:RE:RE:RE:RE:RE:RE:new video on twitter 56 mins ago

Intelligent??
did you read what you sent to the last lines?

However, an ideal test would analyze blood samples instead of saliva, which is more accurate as it’s less likely to miss the virus. Also, a blood test can measure a patient’s immune response to COVID-19 to see if they’ve built up resistance to future infections — something the new Rutgers test can’t do.

But in the absence of widely-distributed blood tests, the merits of a saliva test over nasal swabs stand to benefit lots of people — and could help the country get a better grip on this outbreak.

Definitely no competition for what Lexagene is doing. Just to make the president happy

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”